Scarica l'app Stockscreener
0.403
4.05%
-0.017
Carisma Therapeutics Inc Borsa (CARM) Ultime notizie
Compass Therapeutics, Inc. (NASDAQ:CMPX) Shares Sold by Millennium Management LLC - Defense World
Carisma Therapeutics, Inc. (NASDAQ:CARM) Stock Position Decreased by Millennium Management LLC - Defense World
Millennium Management LLC Takes Position in Marker Therapeutics, Inc. (NASDAQ:MRKR) - Defense World
Carisma Therapeutics Secures Nasdaq Listing Approval - TipRanks
Is the 250% Carisma Therapeutics Stock (CARM) Surge a Sucker’s Rally? - The Globe and Mail
Dow Rises Over 50 Points; US Inflation Rate Increases In May - Benzinga
Carisma Therapeutics Stock (CARM) Retreats 35% After a Massive Rally - TipRanks
US Stocks Mixed; JM Smucker Shares Plunge After Q4 Results - Benzinga
Pre-market Movers: EVGN, WINT, CARM, UNCY... - RTTNews
Why Casey's General Stores Shares Are Trading Higher By Around 10%; Here Are 20 Stocks Moving Premarket - Benzinga
Carisma Therapeutics, Inc. (NASDAQ:CARM) Given Average Recommendation of “Hold” by Brokerages - Defense World
Carisma Therapeutics Reports Q1 2025 Financial Results - TipRanks
Carisma Therapeutics Inc (CARM): An Important Analyst Insights - Stocksregister
Layoff Tracker: Eikon Cuts Workforce by 15%, Citing ‘External Forces’ - BioSpace
Carisma Therapeutics Inc (NASDAQ: CARM) Stock Sentiment: What’s Wall Street Saying? - Stocksregister
Carisma Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Pre-market Movers: LUCY, ALUR, PLRZ, AXDX... - RTTNews
Financial Metrics Unveiled: Carisma Therapeutics Inc (CARM)’s Key Ratios in the Spotlight - DWinneX
Carisma Therapeutics Inc expected to post a loss of 10 cents a shareEarnings Preview - TradingView
Caribou cuts 32% of staff, further purges pipeline to focus on 2 oncology CAR-T prospects - Fierce Biotech
Carisma Therapeutics to Present at Upcoming Conferences - Seeking Alpha
Biopharma restructurings reflect strategy of short-term pain for long-term gains - BioWorld MedTech
Carisma Therapeutics, Inc. (NASDAQ:CARM) Given Average Rating of “Hold” by Analysts - Defense World
Sagimet Biosciences (NASDAQ:SGMT) and Carisma Therapeutics (NASDAQ:CARM) Head-To-Head Review - Defense World
Philly weekly roundup: Carisma Therapeutics layoffs; PPA's AI ticketing; HiveBio's first cohort - Technical.ly
Carisma Therapeutics Inc’s Market Journey: Closing Weak at 0.19, Down -0.26 - DWinneX
CARISMA THERAPEUTICS Earnings Preview: Recent $CARM Insider Trading, Hedge Fund Activity, and More - Nasdaq
Carisma Therapeutics Focuses on Strategic Alternatives Amid Revised Operating Plan - MSN
Philly’s Carisma Therapeutics slashed its workforce to 6 from 46 for sale or wind down - MSN
Carisma Therapeutics Full Year 2024 Earnings: Misses Expectations - Yahoo Finance
Carisma Therapeutics (NASDAQ:CARM) Price Target Lowered to $1.00 at D. Boral Capital - Defense World
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Carisma Therapeutics to Present at AASLD 2024 on Liver Fibrosis Treatment - MSN
Carisma winds down operations, lays off 95% of remaining staff - Fierce Biotech
Penn spinout Carisma Therapeutics lays off 84% of its staff, explores possible sale - The Business Journals
Carisma Therapeutics Provides Corporate Updates - Citizen Tribune
Carisma Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Carisma Therapeutics Board Approves Revised Operating Plan; Reduces Workforce - MarketScreener
Carisma Therapeutics Inc. SEC 10-K Report - TradingView
Carisma Therapeutics Explores Sale Options as Company Halts R&D Programs - Stock Titan
Carisma Therapeutics (CARM) to Release Earnings on Monday - The AM Reporter
Carisma Therapeutics, Inc.'s (NASDAQ:CARM) Business And Shares Still Trailing The Industry - simplywall.st
The Radoff-JEC Group Nominates Three Highly Qualified Candidates for Election to the Atea Pharmaceuticals Board of Directors - Business Wire
Carisma Therapeutics, Inc. (NASDAQ:CARM) Receives Consensus Rating of “Hold” from Analysts - Defense World
0.68%
0.50%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):